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Aims: Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to constitute conduits
for the tumor cells to metastasize. We previously demonstrated that endothelin (ET)-1 through its binding with
ETB receptor (ETBR) expressed on lymphatic endothelial cells (LEC), induced cell growth and invasiveness. Since
vascular endothelial growth factor (VEGF)-A/-C/-D, and hypoxia play key role in lymphatic differentiation, in this
studywe investigated the involvement of these growth factors and hypoxia in ET-1-induced lymphangiogenesis.
Main methods: Real time PCR and ELISA were used to quantify VEGF-A/-C/-D. LEC morphological differentiation
was analyzed by tube formation assay on Matrigel.
Key ﬁndings: Hypoxia, as well as ET-1, induced an increase in VEGF-A/-C and -D expression that was reduced in
the presence of a selective ETBR antagonist, BQ788, and enhanced when ET-1 was administered under hypoxic
conditions. We analyzed the role of hypoxia on LEC morphological differentiation, and found that hypoxia in-
creased the formation of vascular-like structures on Matrigel and that in combination with ET-1 this effect
was markedly enhanced. The use of speciﬁc antibodies neutralizing VEGF-A, or recombinant VEGFR-3/(Flt-4)/
Fc that block VEGF-C/-D, inhibited the effect of ET-1 as well that of hypoxia.
Signiﬁcance: These results demonstrated that ET-1 and hypoxia act, at list in part, through VEGF to induce lym-
phangiogenic events and that these two stimuli may cooperate to induce VEGF-A/-C/-D expression and lym-
phatic differentiation. These data further support the role of ET-1 as potent lymphangiogenic factor that relies
on the interplay with hypoxic microenvironment and with VEGF family members.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Metastasization is the leading cause of cancer mortality. Although
numerous studies have identiﬁed genes andmechanisms thatmodulate
the metastasization process, our knowledge about how cancer cells ini-
tially gain access to vascular and/or the lymphatic system is limited
(Alitalo et al., 2005). The lymphatic spreading can occur by invasion of
tumor cells in pre-existing lymphatic vessels and in intratumoral net-
works of newly formed lymphatic network induced by tumor cells, in-
ﬂammatory and stromal cells (Albrecht and Christofori, 2011). The
identiﬁcation of mechanisms that control lymphatic vessel growth is
likely to contribute to the development of therapies aimed at prevent-
ing lymphatic metastases. Because of their common origin, lymphan-
giogenesis, as well as angiogenesis, relies on the interplay of several
angio- and lymphoangiogenic factors and receptors (Mäkinen et al.,lar Pathology, Regina Elena
me, Italy.
lla@ifo.it (F. Spinella).
Y-NC-ND license.2007). Members of the vascular endothelial growth factor (VEGF) fam-
ily, VEGF-C and VEGF-D, are so far the best-characterized lymphangio-
genic factors that bind the VEGF receptor-3 (VEGFR-3). In normal
adult tissues, VEGFR-3 expression is largely restricted to the lymphatic
endothelium, where it promotes lymphatic endothelial cell prolifera-
tion (LEC), migration, and survival (Mäkinen et al., 2001). In addition
to VEGF-C and VEGF-D, VEGF-A also stimulates lymphatic growth in sev-
eral experimental systems, and the activation of its receptor VEGFR-2 re-
sults into an increase of lymphatic metastasization (Cursiefen et al.,
2004; Zeng et al., 2006; Halin et al., 2007). Preclinical and clinical studies
indicate that these signaling molecules regulate concomitantly blood
and lymphatic vessels suggesting a relationship between angio- and
lymphangiogenesis, and that the concomitant blockade of these has an
additive effect to inhibit tumor growth (Tvorogov et al., 2010; Albrecht
and Christofori, 2011; Witte et al., 2011). We previously demonstrated
that the endothelin (ET-1) axis promotes the growth and differentiation
of LEC puriﬁed from human lymph nodes in vitro and in vivo providing
the ﬁrst evidence that ET-1 axis may act also as a lymphangiogenic me-
diator (Spinella et al., 2009). Moreover, it has been recently suggested
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tumor lymphangiogenesis (Cueni et al., 2010). The ET-1 family consists
of three small structurally related, 21-aa vasoactive peptides (ET-1, ET-
2, and ET-3), and two G-protein-coupled receptors namely ETAR and
ETBR (Morbidelli et al., 1995; Davenport and Maguire, 2006; Thorin and
Webb, 2010). ET genes are readily inducible by growth factors, oncogenes,
cytokines and hypoxia, and have been implicated in the pathophysiology
of a wide range of human tumors, including ovarian carcinoma and mel-
anoma (Nelson et al., 2003; Grimshaw, 2007; Rosanò et al., 2009; Spinella
et al., 2010a). ET-1 family members are also expressed by lymphatic en-
dothelial cells and the coordinated action of ETBR and ETAR, expressed
in the endothelium and in smooth muscle cells, respectively, modulates
lymphatic vascular tone (Reeder and Ferguson, 1996; Marchetti et al.,
1997). Recently, we demonstrated that the activation of ETBR by ET-1 in
LEC is also implicated in mediating various stages of lymphangiogenesis,
including matrix-metalloproteinase (MMP) activation, a prerequisite for
LEC invasion (Spinella et al., 2010b). ET-1-induced effects on LEC are abol-
ished by ETBR antagonists, suggesting that this receptor may represent a
potential target to inhibit lymphangiogenesis (Spinella et al., 2009,
2010b). Among microenvironmental components, hypoxia represents
one of the principal angiogenic stimuli, and it has been proposed to be
also implicated in controlling lymphangiogenesis (Irigoyen et al., 2007;
Ota et al., 2007; Voss et al., 2010). We previously demonstrated that ET-
1 may share with hypoxia a similar molecular mechanism through
which regulates VEGF-A expression and that under hypoxic conditions
this effect was increased (Spinella et al., 2002). Moreover, in LEC we ob-
served that hypoxia increased hypoxia-inducible factor (HIF)-1α, the
principal transcription factor regulating VEGF-A expression, supporting
the role of hypoxia as inducer of lymphangiogenesis (Spinella et al.,
2009). Here we show that exposing LEC to ET-1 or under hypoxic condi-
tion led to the increase in VEGF-C, -D and -A production, and that this ef-
fect is ampliﬁed when ET-1 is added under hypoxic conditions. At
functional level, ET-1 and hypoxia signiﬁcantly increase the number and
the length of vascular-like tubules formed by LEC. Moreover neutraliza-
tion of VEGF-A and/or VEGF-C and -D results in a marked reduction in
ET-1- as well hypoxia-induced formation of a lymphatic endothelial net-
works. These results demonstrating the role of ET-1 on inducing lym-
phangiogenesis and in potentiating hypoxia effect provide new insight
in the mechanism by which ET-1 may interact with microenvironment
component and regulate lymphangiogenesis.
Materials and methods
Lymphatic endothelial cell puriﬁcation and cell cultures
Human lymph node specimens were obtained according to the
guidelines of Helsinki Declaration from patients undergoing surgical
procedures for non-infectious or neoplastic conditions. Lymph nodal
LEC were isolated as previously described (Garrafa et al., 2005, 2006;
Spinella et al., 2009). Cells were grown on collagen type I-coated ﬂasks
(5 μg/cm2; BoehringerMannheim) in EGM-2MV (Lonza, Basel Switzer-
land). To expose cells to hypoxia, amodular incubator was usedwith an
atmosphere setting of 5% CO2, 95% N2, and 1% O2. ET-1 (Peninsula Lab-
oratories, Belmont, CA ) was used at 100 nM, and VEGF-C was used at
50 ng/ml (R&D Systems, Minneapolis, MN). When BQ788 1 μM (Penin-
sula Laboratories), 100 ng/ml anti-VEGF-A or recombinant VEGFR-3
(Flt-4)/Fc (R&D Systems) were tested, they were added 30 min before
the stimuli.
Quantitative real-time-PCR
Total RNA was isolated using the Trizol (Invitrogen, Grand Island,
NY, USA) according to the manufacturer's protocol. Five micrograms
of RNA was reversed transcribed using SuperScript® VILOis™ cDNA
synthesis kit (Invitrogen). Quantitative real-time-PCR was performed
by using LightCycler rapid thermal cycler system (Roche Diagnostics,Mannheim, Germany) according to the manufacturer's instructions.
Reaction was performed in 20 μl volume with 0.3 μM primers, by
using LightCycler-FastStart DNA Master Plus SYBR Green mix (Roche
Diagnostics) from 1 μl cDNA under the following conditions: denatur-
ation at 95 °C for 5 min; melting at 95 °C for 10s; annealing between
58 °C for 10s; extension at 72 °C for 10s. Primers used were as follows:
VEGF-C (forward) 5′-GTGTCCAGTGTAGATGAACTC-3′ and (reverse) 5′ –
ATCTGTAGACGGACACACATG-3′; VEGF-D (forward) 5′-GTTGCAATGAA-
GAGAGCCTT-3′ and (reverse) 5′-TCCCATAGCATGTCAATAGG-3′; VEGF-A
(forward) 5′-CCTCAGTGGGCACACACACTCC-3′ and (reverse) 5′-CGAAAC-
CATGAACTTTCTGC-3′; cyclophilin-A (forward) 5′-TTCATCTGCACTGCCA-
AGAC-3′ and (reverse) 5′-TGGAGTTGTCCACAGTCAGC-3′. The number of
each gene-ampliﬁed product was normalized to the number of
cyclophilin-A ampliﬁed product and expressed as copy numbers over
cyclophilin-A (×10−3).
ELISA
The VEGF-A protein levels in the conditioned media were deter-
mined in duplicate by ELISA using the Quantikine Human VEGF immu-
noassay kit (R&D Systems). The sensitivity of the assay is b5.0 pg/ml.
Intra-assay and interassay variations were 5.4% and 7.3%, respectively.
Human VEGF-C Quantikine ELISA Kit (R&D System) was used for
VEGF-C level determination in LEC media. The sensitivity of the assay
is 13.3 pg/ml. Intra-assay and interassay variations were 6.9% and
9.6%, respectively
In vitro tube formation assay
Tube forming activity was analyzed as previously described
(Spinella et al., 2009). In brief, 50 μl of Matrigel (Cultrex, basal mem-
brane extract, Trevigen, 12.7 mg/ml) was dropped onto each well of a
96-well plate and allowed to solidify for 1 h at 37 °C in humidiﬁed 5%
CO2 incubator. One to 5×104 LEC were plated in the presence of
100 nM ET-1 or 50 ng/ml VEGF-C, and the cells were cultured under
normoxia or hypoxia. When 100 ng/ml anti-VEGF-A or recombinant
VEGFR-3 (Flt-4)/Fc was tested they were added 30 min before the
stimuli. Formation of tube-like structures was photographed after
24 h using light microscopy and quantiﬁed by counting the number
of tubules intersections and the length of tubes in 10 randomly cho-
sen ﬁelds using Scion image analysis program. Magniﬁcation 200×.
Statistical analysis
Results were the means±SD from at least ﬁve sets of replicated
experiments, and in each set, measurements were made in triplicate
for real-time PCR or duplicate for ELISA and capillary-like structure
formation assays. Data were analyzed by one-way ANOVA followed
by Tukey's multiple comparison tests. Data were sampled from popu-
lation with identical SDs as tested by Barlett method and followed
Gaussian distribution as tested by Kolmogorov–Smirnov methods.
p Values were signiﬁcant at pb0.05 using PRISM software (GraphPad
Software, Inc., San Diego, CA).
Results
ET-1 and hypoxia induce VEGF-A, -C and-D expression and production
VEGF-A, VEGF-C and VEGF-D represent the principal mediators of
lymphangiogenesis, and recent data argue for a more relevant role for
hypoxia in controlling their expression in lymphatic (Irigoyen et al.,
2007; Ota et al., 2007; Spinella et al., 2009). Here we monitored the
capacity of ET-1 and hypoxia to cooperatively increase the expression
of these growth factors. Highly puriﬁed human LEC were stimulated
with ET-1 and/or cultured under hypoxic conditions for 6 or 24 h,
and mRNA or conditioned media were analyzed by real time RT-
PCR, or ELISA, respectively. ET-1, as well as hypoxia, signiﬁcantly
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versus control; Fig. 1A) (VEGF-C and -A mRNA n=6; pb0.001 versus
control; Fig. 1B and C) and protein levels (n=5; pb0.001 versus con-
trol; Fig. 1D). To investigate whether ET-1 may inﬂuence hypoxic re-
sponse cells were pretreated with a selective ETBR antagonist,
BQ788, and exposed to hypoxic conditions. As shown in Fig. 1, in
the presence of BQ788 the capacity of hypoxia to up-regulate
VEGF-D, -C and -A mRNA levels was attenuated (VEGF-D mRNA
n=6; pb0.05 versus hypoxic control, Fig. 1 A) (VEGF-C and -A
mRNA n=6; pb0.001 versus hypoxic control). Moreover, simulta-
neous stimulation of LEC with ET-1 and hypoxia resulted in a further in-
crease in VEGF-D, -C and VEGF-A mRNA (n=6; pb0.001 versus ET-1;
Fig. 1A–C), and protein levels compared to ET-1 alone (n=5; pb0.001;
Fig. 1D). Taken together, these results suggest that ET-1 may induce
VEGF-A, -C and-D expression, and production in LEC and interact with
hypoxia to amplify these effects on lymphangiogenic mediators.
ET-1 induces lymphangiogenesis through VEGF-A and VEGF-C production
To investigate the functional signiﬁcance of ET-1- and hypoxia-
induced VEGF-A, VEGF-C and -D we neutralized these growth factors
and monitored the capacity of LEC to form vascular-like structures on
Matrigel, an assay that permits to measure cell adhesion, migration,
protease activity, and tubule formation capacity. Treatment with ET-
1 or hypoxia induced the formation of tube-like structures compared
to the control cells (Fig. 2A). To investigate whether ET-1 and hypoxia
may cooperate in the formation of vascular-like structures, LEC were
simultaneously stimulated with hypoxia and ET-1. In the presence of
anti-VEGF-A, or in the presence of recombinant human VEGFR-3
(Flt4)/Fc chimera protein (VEGFR-3/Ig), which has been shown to
bind to both VEGF-D and VEGF-C and to block ligand/receptor binding
(Su et al., 2006), the effect of ET-1 as well as that of hypoxia was re-
duced (Fig. 2A) indicating that VEGF-C and VEGF-A are involved in
mediating ET-1 and hypoxia actions. Quantitative analysis demon-
strated that ET-1 induced a signiﬁcant increase in the number of in-
tersection between the tube-like structures and in their length
compared to the control (n=10; pb0.001) (Fig. 2B). In the presenceFig.1. ET-1 and hypoxia cooperate to induce VEGF-A, VEGF-C and -D in LEC through ETBR.H
cultured under normoxia or hypoxic conditions. After 6 h total RNA was extracted and VEGF
Results are expressed as copy numbers of VEGF-D, VEGF-C or VEGF-A transcripts over cyclop
compared to ET-1, and *** pb0.05 compared to hypoxic control. In B and C * pb0.001 compa
trol. (D) Cells were stimulated with 100 nM ET-1 and/or cultured under normoxia or hypox
duction by ELISA. Bars, ±SD. (n=5). *, pb0.001 compared to control in normoxia; **, pb0of anti-VEGF-A or rhVEGFR-3 (Flt4)/Fc lower number of intersection
and length of tube-like structures were monitored (Fig. 2B). There-
fore, we next combined recombinant VEGFR-3/Fc and anti-VEGF-A.
In these conditions the number and the length of tube-like structures
was reduced approximately 60% compared to ET-1 alone (pb0.001;
n=10) (Fig. 2B), further supporting the notion that ET-1 may act in
a VEGF-mediated mechanism in controlling lymphangiogenesis. Sim-
ilar results were observed when LEC were pretreated with anti-VEGF-
A or recombinant VEGFR-3 and cultured under hypoxic conditions
(Fig. 2A). There were lower numbers of intersections between tubes
and their length was smaller in the presence of anti-VEGF-A or re-
combinant VEGFR-3/Fc (pb0.001; n=10) than in hypoxia (Fig. 2B).
When neutralizing antibodies were combined, the effect of hypoxia
was even more inhibited (Fig. 2B), suggesting that both VEGF-A and
VEGF-C are required by hypoxia to induce tube-like structures on
LEC. As positive control we monitored the effect of VEGF-C and
VEGFR-3/Fc on vascular-like structure formation of LEC under nor-
moxic conditions. The effect of VEGF-C was completely impaired by
recombinant VEGFR-3/Fc (Fig. 3A and B). These results indicate that
ET-1 and hypoxia act through a common mechanism that involves
VEGF-mediated signaling pathway and that both stimuli may cooper-
ate to enhance lymphangiogenesis.
Discussion
ET-1 acts as a tumorigenic aswell as an angiogenic factor, and recent
reports demonstrated that the activation of ETBR in lymphatic endothe-
lial cells led to a potent lymphangiogenic effect. ET-1 has been demon-
strated to induce LEC proliferation, growth and differentiation
highlighting the potential role of ETBR as a molecular target to control
lymphangiogenesis (Spinella et al., 2009; Cueni et al., 2010). In this
study we further investigated the molecular mechanism through
which ET-1 regulates LEC behavior. Moreover, the role the interaction
between ET-1 and hypoxia increases cellular responsiveness was also
addressed. We found that ET-1, as well as hypoxia, increased VEGF-A,
VEGF-C and -D expression that was further enhanced when ET-1 was
administered under hypoxic conditions. By monitoring the capacity ofighly puriﬁed human LEC were stimulated with 100 nM ET-1 or with 1 μM BQ788 and
-D (A), VEGF-C (B) or VEGF-A (C) transcript levels were quantiﬁed by real time RT-PCR.
hilin-A. Bars, ±SD (n=6). In A * pb0.01 compared to control in normoxia, ** pb0.001
red to control, ** pb0.001 compared to ET-1, and *** pb0.01 compared to hypoxic con-
ic conditions for 24 h, and conditioned media was analyzed for VEGF-C or VEGF-A pro-
.001 compared to control in hypoxia.
Fig. 2. ET-1 and hypoxia induce tube like structure formation through VEGFmembers.Tube-like structure formation wasmonitored in LEC seeded on Cultrex. (A) Representative images
from three independent experiments of LEC treatedwith 100 nMET-1 alone or in combinationwith anti-VEGF-A and/or recombinant VEGFR-3/Fc for 24 h in normoxia, or cultured under
hypoxic condition. Quantiﬁcation of cell intersection number (B) and tubule length (C) of experiment described in A. Data shown in B, (left panel) bars, ±SD. #, pb0.001, compared to
the control; **, pb0.001 compared to the ET-1. ***, pb0.01 compared to ET-1. Data shown in B (right panel). Bars, ±SD. #, pb0.001, compared to the control. Data shown in C (left panel).
Bars, ±SD. #, pb0.001, compared to the control; **, pb0.001 compared to the ET-1. Data shown in C (right panel) panel. Bars, ±SD; #, pb0.001, compared to the control.
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sional cell culture, we found that ET-1 cooperateswith hypoxia through
VEGF-A, VEGF-C and -D to induce a rich network of interconnected
tube-like structures. Recently several newmediators of lymphangiogen-
esis have been identiﬁed that act through a direct mechanism or through
VEGF family members (Cao et al., 2006; Kang et al., 2009; Larrieu-
Lahargue et al., 2010; Sawane et al., 2011). Although VEGF-C and VEGF-
D represent the principal mediators of lymphangiogenic process during
development and under pathological condition, VEGF-A has been also
demonstrated to stimulate this process due to its capacity to bind
VEGFR-3 expressed on LEC (Koch et al., 2011). On the other hand VEGF-
C andVEGF-Dmay bind VEGFR-2 also expressed by LEC and activate lym-
phatic cells (Goldman et al., 2007). Here we describe that ET-1 induced
VEGF members. To investigate more deeply their involvement in ET-1-induced lymphangiogenesis, we selectively neutralized VEGF-A and/or
VEGF-C and -D by anti-VEGF-A and by human recombinant VEGFR-3. In
this condition endogenous as well as the ET-1-induced VEGF-A or
VEGF-C and -D are virtually inactive. When we tested the capacity of
ET-1 to induce LEC growth, differentiation and invasiveness by a 3 di-
mensional test, we found that inactivation of VEGF-A or VEGF-C signif-
icantly, but not completely, reduced the effect of ET-1. Interestingly,
when VEGF-A, VEGF-C and -D were simultaneously neutralized, the ef-
fect of ET-1 was only partially reduced, indicating that ET-1, besides
being a direct modulator of lymphangiogenesis, may also act in a
VEGF-dependent manner. On this regard we previously demonstrated
that the induction of VEGF-A was signiﬁcantly induced after 6 h of
stimulation while ET-1 through ETBR rapidly activated MAPK and
AKT, intracellular signaling molecules implicated in transducing
Fig. 3. VEGF-C induces tube like structure formation through VEGFR-3 LEC were seeded on Cultrex, pretreated with recombinant VEGFR-3/Fc and stimulated with 50 ng/ml VEGF-C.
Tube-like structure formation was monitored and photographed after 24h (A). Tube formation was quantiﬁed by measuring tubule length (B). Data shown in (A) are representative
images from three independent experiments. Data shown in (B) Bars, ±SD. #, pb0.001, compared to the C, **, pb0.001, compared to the VEGF-C.
642 E. Garrafa et al. / Life Sciences 19 (2012) 638–643proliferation and differentiation processes (Spinella et al., 2009).
These data suggest that a direct involvement of ETBR-mediated sig-
naling pathway is implicated in the early events after ET-1 stimula-
tion, while ET-1-induced VEGF members may occur later to prolong
the effect of ET-1. Recent studies have also shown that hypoxia, be-
sides regulating neoangiogenesis, can modulate lymphangiogenesis.
Genomewide analysis of LEC exposed to low oxygen conditions indi-
cated that hypoxia is capable of increasing VEGF-C, and VEGF-A
mRNA (Irigoyen et al., 2007; Ota et al., 2007). In addition, in LEC hyp-
oxia has been shown to enhance stabilization of HIF-1α, the main
transcription factor controlling VEGF-A expression. In this context,
we demonstrated that ET-1, not differently from hypoxia, triggered
an accumulation of HIF-1α followed by an HIF-1α-mediated upregu-
lation of VEGF-C and VEGF-A, suggesting that ET-1 axis and hypoxia
may act on HIF-1 α-dependent machinery to promote lymphangio-
genesis via VEGF family members (Spinella et al., 2009). Our ﬁndings
demonstrating that hypoxia regulates VEGF-A, VEGF-C and -D, and
that blockade of these growth factors inhibits hypoxia-induced
vascular-like structures in LEC further support that like angiogenesis,
hypoxia increases lymphangiogenesis through VEGF-family mem-
bers. Overall, our observations demonstrate that ET-1 and hypoxia
stimulate VEGF-A, VEGF-C and -D expression, and these factors
have addictive effects on the formation of vascular-like structures.
The mechanisms underlying the cooperation between ET-1 and hyp-
oxia are not well deﬁned. In our study, the additive actions of ET-1
and hypoxia on VEGF member expression and vessel formation re-
ﬂect the independence between their individual signaling mecha-
nisms. Interestingly, we found that blockade of ETBR by BQ788
lowered the hypoxia-induced VEGF-A and VEGF-C expression, sug-
gesting that the effects of hypoxia may be, at least in part, mediated
by ET-1/ETBR axis. It is also interesting to note that, besides VEGF, ET-
1 is an HIF-1α target gene; therefore under hypoxic conditions ET-1
levels it may be also increased and, in turn, it contributes to VEGF in-
crease suggesting a more complex regulation between hypoxia,
VEGF, and ET-1 that modulates lymphangiogenic responses. This hy-
pothesis needs to be further investigated to obtain more informationon the complexity of lymphangiogenic process especially during
pathological condition such as tumor in which the interplay between
hypoxia microenvironment and tumor cells permits a selective
growth advances for cancer cells (Guise, 2010).
Conclusions
Similar to angiogenesis, our results demonstrate that the process of
lymphangiogenesis is ﬁnely tuned by the interplay ofmultiple hypoxia-
regulated growth factors, such as VEGFmembers and ET-1 axis with the
hypoxic microenvironment. In view of the correlation between tumor
expression of ET-1 axis and lymphatic metastasis (Wülﬁng et al.,
2003), the present results raise the possibility that ETBR activation con-
tributes to tumor progression by direct effects on tumor cells and on LEC
disclosing a yet unidentiﬁed regulatory mechanism, which relies on the
involvement of tumor microenvironment.
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